Abstract
Leishmaniasis is an important vector-borne neglected tropical disease caused by Leishmania parasites. Current anti-Leishmania chemotherapy is unsatisfactory, justifying the continued search for alternative treatment options. Herein, we demonstrate that luciferase-expressing Leishmania infantum axenic amastigotes, unlike promastigotes, are highly infectious to BALB/c mice and thus generate a robust bioluminescent signal in target organs, such as the liver and the spleen, as early as two weeks after infection. Treatment with the reference drugs amphotericin B and miltefosine was effective at reducing parasite burdens. This model allows the assessment of treatment efficacy using whole-mouse bioluminescence imaging without the need to wait several weeks for spleen infections to be detectable by this non-invasive method. In conclusion, we propose the use of this model in an initial approach to evaluate the treatment efficacy of promising chemical entities without having to sacrifice large numbers of animals or to wait several days for a readout.
Similar content being viewed by others
Introduction
Leishmaniasis is a vector-borne parasitic disease caused by over 20 Leishmania species1. It affects approximately 12 million people worldwide, with up to 1 million new cases every year1. Visceral leishmaniasis (VL), the most severe form of the disease, is fatal if left untreated. VL is mainly associated with Leishmania infantum (New and Old Worlds) or Leishmania donovani (Old World) infections, as these parasites are capable of disseminating to the host internal organs, particularly the liver, spleen and bone marrow1,2. As there is still no vaccine available for humans, disease control relies mostly on chemotherapy and vector control. Therefore, the limited and unsatisfactory chemotherapeutic options dictate the need for new drugs3,4. Indeed, every year up to 30,000 individuals suffering from VL die, some of them due to clinical treatment failure (associated with drug resistance, drug quality/misuse and infection status)1,5. Fortunately, neglected tropical diseases such as leishmaniasis have become a relevant part of the global health agenda, with a consequent increase in investment in control strategies6. New leads against leishmaniasis are currently being optimized, while other compounds are already in pre-clinical and clinical stages7,8. Moreover, the recent development of in vitro high-throughput screening programs is expected to feed the anti-Leishmania drug discovery pipeline with new compounds8,9,10, whose efficacy will need to be addressed in vivo. Direct parasite observation remains the gold standard readout of anti-Leishmania drug efficacy in vivo11. However, the traditional parasitological methods used to this end (microscopic analysis of organ biopsies or limiting dilution assays) exhibit some limitations. Besides being labor-intensive and time-consuming, these methods only allow a static evaluation of infection since target organ collection entails euthanasia of the animal8,11. Indeed, the requirement of a large number of animals represents not only a technical but also an ethical limitation8. In vivo imaging techniques, namely those using bioluminescence-based models, have been developed to overcome such drawbacks12. Whole-body bioluminescence imaging has been aplied to detect L. infantum infection in mice13,14,15 and hamsters16,17. The latter develop similar clinicopathological features of VL in humans but several restrictions associated with their use, which include cost and the prolonged time of infection until symptoms appear, support the use of the mice model. In fact, mice are the most comonly used model to evalute the anti-leishmanial activity of promising chemical entities in an initial approach. Infections with L. infantum expressing firefly luciferase have been described and validated to study drug efficacy in vivo13,14,15. However, in these models, more than a month post-infection is normally required to generate robust bioluminescent signal in the spleen13,14,15. Mouse infections with L. infantum are commonly performed by injecting promastigotes, the flagellated extracellular parasite stage transmitted to the mammalian host following the bite of an infected sandfly vector. In the mammalian host, promastigotes are captured by phagocytic cells and transform into non-motile amastigotes inside the phagolysosome. The diferentiation from promastigotes to amastigotes is triggered by elevated temperature and drop in pH18. These conditions can be reproduced in vitro for culturing several Leishmania species19,20, including L. infantum, as axenic amastigotes21. These forms efficiently infect macrophages and have been used to identify compounds that are active against the intracellular Leishmania stage22,23,24. In this work, we investigated the infectivity of luciferase-expressing L. infantum axenic amastigotes in BALB/c mice. We found that this parasite form is highly infectious and generates a robust bioluminescent signal in target organs suitable for the evaluation of treatment efficacy using whole-mouse live imaging.
Results and Discussion
In a previous study, we demonstrated that luciferase-expressing L. infantum axenic amastigotes22 injected intravenously generate a robust bioluminescent signal in mice on the first day of infection25. To assess if this signal could still be detected at later time points post-infection, thus allowing the assessment of treatment efficacy in vivo, we infected BALB/c mice with 108 L. infantum axenic amastigotes or promastigotes intravenously (IV) (Fig. 1). Mice were then imaged 14 days post-infection (Fig. 1A) using an IVIS Lumina LT (PerkinElmer), 10 minutes after the administration of luciferin. The ventral fur was shaved to maximize photons detection and the mice placed in the dorsal position were angled to increase the detection of the signal coming from the spleen. The spatial distribution of the bioluminescent signal indicates parasite establishment in the anatomical regions encompassing target organs such as the liver, spleen, lymph nodes and bone marrow (Fig. 1A). Interestingly, mice infected with the same inoculum of L. infantum promastigotes exhibited almost no detectable bioluminescent signal (Fig. 1B). Using the Living Image software, elliptical regions (ROIs) were drawn to quantify bioluminescent signal in the anatomical regions of the liver, spleen, lymph nodes and bone marrow (the last two inferred from the signal of the left leg; Fig. 1A,B). The bioluminescent signal evaluated by the average radiance (photons/second/cm2/steradian) of the above ROIs was significantly higher in the animals infected with axenic amastigotes than in animals infected with promastigotes (Fig. 1C). Indeed, the signal in the spleen and leg of the animals infected with promastigotes was below the detection limit (Fig. 1C), which corresponds to the signal obtained when the above ROIs were applied to the images generated in the non-infected mice following luciferin administration.
To evaluate whether the differences in the bioluminescent signal detected in amastigote- and promastigote-infected mice were due to distinct infective capacities, parasite burdens in the liver, spleen and bone marrow were evaluated using the gold standard limiting dilution assay26. In fact, promastigote infection yielded significantly lower parasite burdens in these organs when compared to infections performed with axenic amastigotes (Fig. 1D). This indicates that the difference in the signal intensity was most likely due to a reduced number of parasites in these organs. Interestingly, in vitro data demonstrates that axenic amastigotes have an increased capacity to originate persistent infections in macrophages when compared with the promastigotes (Fig. 2).
This was observed using in vitro infections of peritoneal macrophages from BALB/c mice with axenic amastigotes and promastigotes at a ratio of 2 (data not shown) and 10 parasites per cell (Fig. 2). Both parasite forms were capable of infecting a similar percentage of macrophages as no significant differences were seen at 4 hours post-infection (Fig. 2A,B). However, the cells infected with axenic amastigotes were more parasitized when compared to promastigotes infections (Fig. 2A–C). This difference increases with time and at 72 hours post-infection the mean value of parasites per cell is ~10 versus ~3 for cells infected with axenic amastigotes or promastigotes respectively. Ultimately, this increased capacity of axenic amastigotes to originate infections that persist inside macrophages may contribute to their higher infectivity in vivo.
Considering that animals infected with axenic amastigotes yielded an early and sustained detectable bioluminescent signal in the main target organs, we tested the potential of this model to evaluate, using whole-mouse imaging, the effectiveness of in vivo treatments against L. infantum. Infected animals were treated with miltefosine at 20 mg/kg/day (per os) or amphotericin B at 1 mg/kg/day (IV) for four days starting from day 15 post-infection (Fig. 3A). This time-point was chosen due to a compromise between bioluminescence signal and parasite establishment in the target organs (Supplementary Figure 1A,B; splenic burdens plateau from 15 days post-infection, while signal in the liver is reproducibly detected at this time-point). Imaging was performed right before treatment (day 15 post-infection), and one (day 19 post-infection) and three days (day 21 post-infection) after the last day of treatment (Fig. 3B). On day 21 post-infection mice were sacrificed and the liver, spleen and bone marrow were harvested for parasite burden assessment by limiting dilution. As anticipated, the short miltefosine treatment was sufficient to significantly decrease the bioluminescent signal in the ROIs defined for the liver and spleen (Fig. 3C). Amphotericin B was not as effective, although a statistically significant difference was still obtained in the spleen when compared to the untreated animals. Similar results were observed when the parasite burden was determined by the limiting dilution method (Fig. 3D). However, parasites were still detected in animals whose bioluminescent signal was below background levels (Fig. 3D). Therefore, despite lower sensitivity, whole-animal bioluminescence imaging enabled the determination of the effectiveness of different treatments in reducing spleen and liver parasite burdens. We further evaluated the correlation between the two techniques used to determine parasite burdens in the liver and the spleen (Fig. 4). Average radiance values superior to the 99% confidence interval (GraphPad Prism 6.0 version) of the mean of the signal emitted by uninfected animals were plotted against the respective number of parasites per gram of liver (Fig. 4A) or spleen (Fig. 4B). Statistical significance, which translates into a positive correlation (GraphPad Prism 6.0 version), was found for both the liver and spleen determinations, evidencing the validity of this in vivo model.
Interestingly, while splenic parasite burdens remain constant up to at least week 14, as evaluated by either bioluminescence imaging or limiting dilution assay (Supplementary Figure 1A,B), liver burdens decrease to bioluminescent background levels as observed at eight weeks post-infection, suggesting the host could be controlling the infection in this organ (Supplementary Figure 1A)27, as it is observed in other murine models of visceral disease due to the known organ-specific immunity28.
In conclusion, we demonstrate the superior infectivity of L. infantum axenic amastigotes compared to promastigotes. This superior infectivity has also been reported for other Leishmania species either responsible for cutaneous (L. mexicana and L. major)29,30 or visceral infection (L. donovani)30,31. We propose the use of this rapid bioluminescence-based model for a time and cost effective preliminary in vivo testing of promising compounds against L. infantum. This minimally invasive method not only allows the assessment of treatment efficacy but also enables the adjustment of treatment regimens in a simple approach without the need to sacrifice large numbers of animals or to wait several days for a reliable readout. We expect this model to be a useful addition to the tools available to assist in the search for novel drugs to treat VL.
Materials and Methods
Ethics statement
The Instituto de Biologia Molecular e Celular.Instituto Nacional de Engenharia Biomédica Animal Ethics Committees approved all the experiments carried out on mice and the project was licenced by the Portuguese National Authority for Animal Health, in accordance to the statements on the directive 2010/63/EU of the European Parliament and Council.
Mice and parasites
Six- to seven-week-old BALB/c mice were purchased from Charles River or the i3S animal facility. The L. infantum line used in this study is a clonal line (MHOM/MA/67/ITMAP-263) with an episomal expression of firefly luciferase under the control of the alpha-tubulin intergenic region (pGMαNEOαLUC vector)22. Both promastigotes and amastigotes were cultured under drug pressure (60 μg/ml of neomycin) in complete RPMI 1640 at 27 °C or complete cell-free medium MAA at 37 °C with 5% CO2, respectively25,32. Axenic amastigotes were differentiated from promastigotes, which in turn were derived from spleen cells recovered from infected BALB/c mice, to maintain parasite infectivity32. Briefly, a single high-density subpassage was performed and after five days these promastigotes were transformed into axenic amastigotes22. For the infections performed in this work, axenic amastigotes and promastigotes were cultured for a maximum of six subpassages.
Mice infections, treatments and parasite load quantification
Promastigotes or axenic amastigotes recovered from a five days old cultures were washed twice with PBS and injected IV in mice (108 parasites in 100 ul PBS). Treatments were performed starting from day 15 post-infection for four consecutive days with miltefosine at 20 mg/kg/day (per os) or amphotericin B at 1 mg/kg/day (IV).
Parasite loads were evaluated using whole-mouse bioluminescent in vivo imaging (IVIS LUMINA LT, Perkin Elmer). Mice had their ventral fur shaved with an appropriate clipper and were anesthetised with 2.5% isoflurane prior to the subcutaneous injection in the neck of 2.4 mg of D-luciferin. After a ten minute incubation time to allow the distribution of the substrate in the body of the anesthetised animals, a ten-minute signal acquisition controlled by the Living Image software (Perkin Elmer) was initiated. At the end of this period, animals returned to their cage and recovered from the anaesthesia33.
Parasite loads were also determined by limiting dilution26,33,34. Briefly, organ homogenates (1 mg of spleen; 4 mg of liver) were subjected to two-fold serial dilutions in quadruplicate with Schneider’s Insect medium in 96-well microtitration plates. The plates were incubated at 27 °C for 15 days and then each well was inspected for the presence or absence of promastigotes. The number of parasites per gram of organ was calculated as previously26,33,34.
Macrophage infections and parasite quantifications
Peritoneal macrophages were collected from BALB/c mice using ice-cold PBS. 2 × 105 peritoneal cells were seeded in 8-well chamber slides (LabteK) and cultured in complete RPMI at 37 °C, 5% CO2. The day after, unattached cells were removed and infections were performed with 2 × 106 promastigotes or axenic amastigotes (corresponding to a 10:1 ratio parasites:cells) in complete RPMI for 4 hours at 37 °C, 5% CO2. Cells were then washed three times with pre-warmed medium to remove extracellular parasites. Cells were either fixed (for the 4 hours post-infection time point) or cultured for 3 additional days. Methanol fixed cells were stained with Hemacolor. The slides were analysed with an Olympus BX63 microscope and the images were taken using the Olympus cellSens software. The percentage of infected cells were determined by counting at least 300 cells per replicate. The number of parasites per infected cell was calculated by counting at least 50 infected cells per replicate.
Statistical analysis
All statistical analyses and graphical representations of the data were performed using GraphPad Prism 6 software. Mann Whitney, one- or two-way analysis of variance (ANOVA) and Student’s t-test were performed and statistical significance was asserted whenever the p value was lower than 0.05 and represented by *(p < 0.05),**(p < 0.01),***(p < 0.001) and ****(p < 0.0001).
Data availability
All data generated or analysed during this study are included in this published article and its Supplementary Information files.
References
WHO. Leishmaniasis, Fact sheet No 375, http://www.who.int/mediacentre/factsheets/fs375/en/ (2017).
Cecilio, P. et al. Deception and manipulation: the arms of leishmania, a successful parasite. Front Immunol 5, 480, https://doi.org/10.3389/fimmu.2014.00480 (2014).
Loureiro, I. et al. Potential drug targets in the pentose phosphate pathway of trypanosomatids. Curr Med Chem 25, 5239–5265, https://doi.org/10.2174/0929867325666171206094752 (2018).
Ponte-Sucre, A. et al. Drug resistance and treatment failure in leishmaniasis: A 21st century challenge. PLoS Negl Trop Dis 11, e0006052, https://doi.org/10.1371/journal.pntd.0006052 (2017).
Moore, E. M. & Lockwood, D. N. Treatment of visceral leishmaniasis. J Glob Infect Dis 2, 151–158, https://doi.org/10.4103/0974-777X.62883 (2010).
Molyneux, D. H., Savioli, L. & Engels, D. Neglected tropical diseases: progress towards addressing the chronic pandemic. Lancet 389, 312–325, https://doi.org/10.1016/S0140-6736(16)30171-4 (2017).
Field, M. C. et al. Anti-trypanosomatid drug discovery: an ongoing challenge and a continuing need. Nat Rev Microbiol 15, 217–231, https://doi.org/10.1038/nrmicro.2016.193 (2017).
Zulfiqar, B., Shelper, T. B. & Avery, V. M. Leishmaniasis drug discovery: recent progress and challenges in assay development. Drug Discov Today 22, 1516–1531, https://doi.org/10.1016/j.drudis.2017.06.004 (2017).
Annang, F. et al. High-throughput screening platform for natural product-based drug discovery against 3 neglected tropical diseases: human African trypanosomiasis, leishmaniasis, and Chagas disease. J Biomol Screen 20, 82–91, https://doi.org/10.1177/1087057114555846 (2015).
Pena, I. et al. New compound sets identified from high throughput phenotypic screening against three kinetoplastid parasites: an open resource. Sci Rep 5, 8771, https://doi.org/10.1038/srep08771 (2015).
Gupta, S. N. Visceral leishmaniasis: experimental models for drug discovery. Indian J Med Res 133, 27–39 (2011).
Avci, P. et al. In-vivo monitoring of infectious diseases in living animals using bioluminescence imaging. Virulence 9, 28–63, https://doi.org/10.1080/21505594.2017.1371897 (2018).
Thalhofer, C. J. et al. In vivo imaging of transgenic Leishmania parasites in a live host. J Vis Exp, e1980, https://doi.org/10.3791/1980 (2010).
Alvarez-Velilla, R. et al. A chronic bioluminescent model of experimental visceral leishmaniasis for accelerating drug discovery. PLoS Negl Trop Dis 13, e0007133, https://doi.org/10.1371/journal.pntd.0007133 (2019).
Michel, G. et al. Luciferase-expressing Leishmania infantum allows the monitoring of amastigote population size, in vivo, ex vivo and in vitro. PLoS Negl Trop Dis 5, e1323, https://doi.org/10.1371/journal.pntd.0001323 (2011).
Reimão, J. Q. et al. Generation of luciferase-expressing Leishmania infantum chagasi and assessment of miltefosine efficacy in infected hamsters through bioimaging. PLoS Negl Trop Dis 9, e0003556, https://doi.org/10.1371/journal.pntd.0003556 (2015).
Rouault, E. et al. Imaging visceral leishmaniasis in real time with golden hamster model: Monitoring the parasite burden and hamster transcripts to further characterize the immunological responses of the host. Parasitol Int 66, 933–939, https://doi.org/10.1016/j.parint.2016.10.020 (2017).
Zilberstein, D. & Shapira, M. The role of pH and temperature in the development of Leishmania parasites. Annu Rev Microbiol 48, 449–470, https://doi.org/10.1146/annurev.mi.48.100194.002313 (1994).
Zilberstein, D. & Nitzan Koren, R. Host-Free Systems for Differentiation of Axenic Leishmania. Methods Mol Biol 1971, 1–8, https://doi.org/10.1007/978-1-4939-9210-2_1 (2019).
Gupta, N., Goyal, N. & Rastogi, A. K. In vitro cultivation and characterization of axenic amastigotes of Leishmania. Trends Parasitol 17, 150–153, https://doi.org/10.1016/s1471-4922(00)01811-0 (2001).
Sereno, D. & Lemesre, J. L. Axenically cultured amastigote forms as an in vitro model for investigation of antileishmanial agents. Antimicrob Agents Chemother 41, 972–976 (1997).
Sereno, D., Roy, G., Lemesre, J. L., Papadopoulou, B. & Ouellette, M. DNA transformation of Leishmania infantum axenic amastigotes and their use in drug screening. Antimicrob Agents Chemother 45, 1168–1173, https://doi.org/10.1128/AAC.45.4.1168-1173.2001 (2001).
Ephros, M., Bitnun, A., Shaked, P., Waldman, E. & Zilberstein, D. Stage-specific activity of pentavalent antimony against Leishmania donovani axenic amastigotes. Antimicrob Agents Chemother 43, 278–282 (1999).
Santarém, N., Tavares, J. & Cordeiro-da-Silva, A. In Vitro Infections of Macrophage-Like Cell Lines with Leishmania infantum for Drug Screening. Methods Mol Biol 1971, 265–277, https://doi.org/10.1007/978-1-4939-9210-2_14 (2019).
Tavares, J., Costa, D. M., Teixeira, A. R., Cordeiro-da-Silva, A. & Amino, R. In vivo imaging of pathogen homing to the host tissues. Methods 127, 37–44, https://doi.org/10.1016/j.ymeth.2017.05.008 (2017).
Buffet, P. A., Sulahian, A., Garin, Y. J., Nassar, N. & Derouin, F. Culture microtitration: a sensitive method for quantifying Leishmania infantum in tissues of infected mice. Antimicrob Agents Chemother 39, 2167–2168 (1995).
Rodrigues, V., Cordeiro-da-Silva, A., Laforge, M., Silvestre, R. & Estaquier, J. Regulation of immunity during visceral Leishmania infection. Parasit Vectors 9, 118, https://doi.org/10.1186/s13071-016-1412-x (2016).
Stanley, A. C. & Engwerda, C. R. Balancing immunity and pathology in visceral leishmaniasis. Immunol Cell Biol 85, 138–147, https://doi.org/10.1038/sj.icb7100011 (2007).
Bates, P. A. et al. Axenic cultivation and characterization of Leishmania mexicana amastigote-like forms. Parasitology 105, 193–202 (1992).
al-Bashir, N. T. et al. Axenic cultivation of amastigotes of Leishmania donovani and Leishmania major and their infectivity. Ann Trop Med Parasitol 86, 487–502 (1992).
Saar, Y. et al. Characterization of developmentally regulated activities in axenic amastigotes of Leishmania donovani. Mol Biochem Parasitol 95, 9–20 (1998).
Moreira, D. et al. Impact of continuous axenic cultivation in Leishmania infantum virulence. PLoS Negl Trop Dis 6, e1469, https://doi.org/10.1371/journal.pntd.0001469 (2012).
Tavares, J., Santarém, N. & Cordeiro-da-Silva, A. Quantification of Leishmania Parasites in Murine Models of Visceral Infection. Methods Mol Biol 1971, 289–301, https://doi.org/10.1007/978-1-4939-9210-2_16 (2019).
Faria, J. et al. Disclosing the essentiality of ribose-5-phosphate isomerase B in Trypanosomatids. Sci Rep 6, 26937, https://doi.org/10.1038/srep26937 (2016).
Acknowledgements
We thank Carla Oliveira from i3S for the support with the statistical analysis. Part of the content of this manuscript has been released as a pre-print in BioRxiv (https://doi.org/10.1101/326355). This work was financed by FEDER - Fundo Europeu de Desenvolvimento Regional funds through the COMPETE 2020 - Operacional Programme for Competitiveness and Internationalisation (POCI), Portugal 2020, and by Portuguese funds through FCT - Fundação para a Ciência e a Tecnologia/Ministério da Ciência, Tecnologia e Ensino Superior in the framework of the project POCI-01-0145-FEDER-031013 (PTDC/SAU-PAR/31013/2017). This work also received funds from: Norte-01-0145-FEDER-000012 “Structured program on bioengineered therapies for infectious diseases and tissue regeneration” of Norte Portugal Regional Operational Programme (NORTE 2020) under the PORTUGAL 2020 Partnership Agreement, through the European Regional Development Fund (FEDER) and through the Research Unit No. 4293; Individual funding from FCT through SFRH/BD/123734/2016 (to DC), SFRH/BD/121252/2016 (to PC) and CEECIND/02362/2017 (to JT).
Author information
Authors and Affiliations
Contributions
J.T., D.C. and P.C. conceived and designed the experiments. A.C.S. contributed with reagents and tools. D.C., P.C. and N.S. performed the experiments. D.C., P.C., N.S., A.C.S. and J.T. analyzed the data. D.C., P.C. and J.T. wrote the manuscript. All the authors reviewed the manuscript.
Corresponding authors
Ethics declarations
Competing interests
The authors declare no competing interests.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary information
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Mendes Costa, D., Cecílio, P., Santarém, N. et al. Murine infection with bioluminescent Leishmania infantum axenic amastigotes applied to drug discovery. Sci Rep 9, 18989 (2019). https://doi.org/10.1038/s41598-019-55474-3
Received:
Accepted:
Published:
DOI: https://doi.org/10.1038/s41598-019-55474-3
This article is cited by
-
Anti-trypanosomatid drug discovery: progress and challenges
Nature Reviews Microbiology (2023)
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.